Aminoglycoside therapy in infectious diseases
- 31 May 2013
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 14 (12) , 1585-1597
Abstract
(2013). Aminoglycoside therapy in infectious diseases. Expert Opinion on Pharmacotherapy: Vol. 14, No. 12, pp. 1585-1597.Keywords
This publication has 88 references indexed in Scilit:
- Pharmacokinetics and Safety of Single and Multiple Doses of ACHN-490 Injection Administered Intravenously in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2011
- Comparative Effectiveness of Aminoglycosides, Polymyxin B, and Tigecycline for Clearance of Carbapenem-Resistant Klebsiella pneumoniae from UrineAntimicrobial Agents and Chemotherapy, 2011
- The usefulness of arbekacin compared to vancomycinEuropean Journal of Clinical Microbiology & Infectious Diseases, 2011
- New developments in aminoglycoside therapy and ototoxicityHearing Research, 2011
- Resistance to empiric antimicrobial treatment predicts outcome in severe sepsis associated with gram‐negative bacteremiaJournal of Hospital Medicine, 2011
- In Vivo Efficacy of the Novel Aminoglycoside ACHN-490 in Murine Infection ModelsAntimicrobial Agents and Chemotherapy, 2011
- Aminoglycoside modifying enzymesDrug Resistance Updates, 2010
- In V itro Activity of the Aminoglycoside Antibiotic Arbekacin against Acinetobacter baumannii-calcoaceticus Isolated from War-Wounded Patients at Walter Reed Army Medical CenterAntimicrobial Agents and Chemotherapy, 2010
- Antistaphylococcal Activity of ACHN-490 Tested Alone and in Combination with Other Agents by Time-Kill AssayAntimicrobial Agents and Chemotherapy, 2010
- ACHN-490, a Neoglycoside with Potent In Vitro Activity against Multidrug-Resistant Klebsiella pneumoniae IsolatesAntimicrobial Agents and Chemotherapy, 2009